Clinical trial · Observational
Transperineal Laser Ablation Treatment (TPLA) for Prostate Cancer (PCa) Registry
Transperineal Laser Ablation Treatment for Prostate Cancer Registry: a Retrospective and Multicenter Evaluation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Rationale: Transperineal laser ablation (TPLA) treatment for prostate cancer (PCa) is a minimal invasive focal therapy technique studied worldwide to determine its efficacy. In pilot studies it has shown to be a safe and feasible technique and it has potential to preserve continence and potency over current standard radical therapies. However, (long-term) treatment outcomes of TPLA for PCa remain largely unknown. The aim of this international retrospective registry is to collect and combine data on patients treated TPLA for PCa in order to provide data on safety, feasibility, functional and oncological outcomes. Objective: To assess safety and feasibility of TPLA for PCa, to assess functional and oncological outcomes of TPLA for PCa and to determine baseline patient characteristics in a multicentre cohort. Study design: This is an international, retrospective observational registry in which data is recorded of patients who have been treated with TPLA for PCa. Study population: Male patients treated with TPLA for PCa. Main study parameters/endpoints: The primary endpoint of this registry is oncological outcomes of TPLA for PCa. Secondary endpoints are safety, feasibility and functional outcomes of TPLA for PCa.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Transperineal Laser Ablation of Prostate Cancer | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Oncological control
- timeFrame
- 12 months
- description
- Oncological control is defined as: a PSA \<=2.0ng/mL than initial PSA and/or no residual tumor or other lesion suspicious for prostate cancer on magnetic resonance imaging and/or no gleason score upgrading on re-biopsy and/or no clinical up-staging of prostate cancer T-stage
Secondary outcomes (7)
- measure
- Continence rate
- timeFrame
- 12 months
- description
- Continence is assessed by usage of number of pads per day, and 0-1 pad per day usage is defined as continent.
- measure
- Potency rate
- timeFrame
- 12 months
- description
- Potency is defined as erectile function sufficient for sexual intercourse, with or without medical aid
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male, histological-confirmed disease of localized prostate cancer, TPLA treatment for PCa is performed Exclusion Criteria: * Age \< 18 years
References
Publications (2)
- DERIVEDde Bie KCC, Cornud FC, Walser EM, van Riel LAMJG, Regusci S, Martins Favre M, Zimmer RE, Galiano M, Manenti G, Micillo A, Oddens JR. One-year Follow-up after US-guided Transperineal Focal Laser Ablation of Localized Prostate Cancer: Worldwide Registry Study. Radiology. 2026 Jun;319(3):e251658. doi: 10.1148/radiol.251658. PMID 42227864
- DERIVEDCornud F, de Bie K, van Riel L, Lefevre A, Camparo P, Galiano M. MRI-directed Micro-US-guided Transperineal Focal Laser Ablation for Localized Prostate Cancer: A 1-year Follow-up Study. Radiology. 2024 Dec;313(3):e233371. doi: 10.1148/radiol.233371. PMID 39718499